Introduction
Topiramate (TPM) is an antiepileptic drug (AED) with a broad range of antiseizure activities. 1 Controlled studies have demonstrated the efficacy of TPM in adults with partial and generalized tonic-clonic seizures. [1] [2] [3] In adult patients with newly diagnosed epilepsy, TPM is at least as effective as therapeutic doses of carbamazepine and valproate. 4 TPM is also effective in children affected by generalized or partial refractory epilepsy, 5 Lennox-Gastaut syndrome, 6, 7 refractory infantile spasms, 8, 9 myoclonic-astatic epilepsy, 10 childhood absence seizures, 11 and as recently reported, in children with refractory status epilepticus. 12, 13 Seizure (2005) Summary Studies of the efficacy of topiramate (TPM) in infants and young children are few. Here we report an open, prospective, and pragmatic study of effectiveness of TPM in terms of epilepsy syndromes, in children aged less than 2 years. The median follow-up period was 11 months. We enrolled 59 children in the study: 22 affected by localization-related epilepsy (LRE), 23 by generalized epilepsy, six by Dravet's syndrome, and eight with unclassifiable epilepsy. TPM was effective (responders showed a decrease of more than 50% in seizure frequency) in 47% of patients, including 13% who were seizure-free at the last visit. TPM was more effective in localization-related epilepsy (48% of responders) than in generalized epilepsy (32% of responders). In the latter group, 19 patients suffered from infantile spasms. Four of six patients with cryptogenic infantile spasms became seizure-free. Of the 13 patients with symptomatic infantile spasms, only one was seizure-free. Results were poor for patients with Dravet's syndrome. In general, TPM was well tolerated. The most frequently reported adverse effects were drowsiness, irritability, hyperthermia, and anorexia.
The present study concludes that TPM is effective for a broad range of seizures in infants and young children and represents a valid therapeutic option in this population. # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Here, we report on the efficacy of TPM as an addon drug in a series of children aged less than 2 years affected by epilepsy.
Patients and methods
In the period between January 1999 and October 2003, 59 children affected by epilepsy were enrolled in the study: 28 girls and 31 boys, with ages ranging from 1 month to 24 months (mean 13 AE 0.8 months). The patients were recruited from our clinic and were selected according to the following criteria: (i) aged less than 2 years; and (ii) seizures refractory to at least one AED. Family and personal histories were recorded and neurological examinations performed on all patients. Biochemical and chromosomal investigations were carried out when considered necessary. Electroencephalograms (EEGs) were recorded during wakefulness, spontaneous sleep, and arousal. Long-term video EEG was performed when considered useful in classifying the type of epilepsy. All patients underwent imaging studies with brain magnetic resonance imaging (MRI). Single-photon emission computed tomography (SPECT) or positron emission tomography (PET) was also performed when considered necessary. Seizure types and epilepsy syndromes were classified in accordance with the International League Against Epilepsy (ILAE) classification of epileptic seizures 14 and epileptic syndromes. 15, 16 Etiology was determined in 30 patients (51%) ( Table 1) . Twenty-two patients (37%) were classified as having localization-related epilepsy (LRE) ( Table 2 ). The two patients with idiopathic LRE (Table 2) were affected by either early-onset occipital seizures or benign partial epilepsy in infancy with secondarily generalized seizures refractory to treatment with carbamazepine. A patient affected by hotwater epilepsy related to a left parietal cortical dysplasia was also included in the group of patients with symptomatic LRE. Ohtahara syndrome was related to diffuse cortical dysplasia. Congenital cytomegalovirus infection was diagnosed in the patient with myoclonic epilepsy and recurrent myoclonus status in non-progressive encephalopathy. 17 Because TPM is not indicated for epileptic therapy in children aged less than 2 years in Italy, informed consent was obtained from the patients' parents. TPM was added to current treatments in an open fashion. When TPM was added on therapy, all patients were under treatment with a number of AEDs ranging from one to three. In detail, 22 patients (37%) were receiving one AED, 24 patients (41%) two AEDs, and 13 patients (22%) three AEDs. Drugs administered at the outset of TPM therapy included valproate (58%), carbamazepine (41%), vigabatrin (37%), phenobarbital (24%), clonazepam (22%), lamotrigine (7%), and chlormethyldiazepam (5%). It is noteworthy that, on starting TPM, 68% of patients (13/19) with infantile spasms were taking vigabatrin only, whereas the remaining patients in this group were treated with polytherapy. Moreover, seven of these patients (37%) had already received adrenocorticotropic hormone (ACTH) when they first arrived under our care. TPM was administered at a daily dose of 0.5-1.0 mg/kg, followed by a week of titration in increments of 1-3 mg/kg, up to a maximum of 10 mg/kg per day. If adverse events occurred, the titration phase was prolonged on the basis of the clinical condition. In patients with infantile spasms, TPM titration was more rapid (over a 7-10-day period) up to a dose 20-25 mg/kg per day, according to the clinical response to the drug. Mean seizure frequency was 43 per month (range 7-68). The age at the onset of epilepsy ranged from 1 to 24 months (mean 9 AE 2.5 months), and the time interval from the onset of epilepsy to the beginning of TPM treatment ranged from 1 to 11 months (mean 5 AE 0.5 months). Efficacy was assessed according to the epilepsy syndrome by parent seizure diaries. Relative to the baseline seizure frequency and severity, the response to TPM treatment was classified as follows: responders (reduction in seizures of more than 50%); minimal (reduction in seizures of less than 50%); unmodified (no change in frequency); and worse (increase in seizure frequency or seizure severity of at least 50%).
During treatment, general clinical and neurological examinations were performed on all patients, every month in patients with infantile spasms and every 3 months in the remaining patients. The presence of adverse events was obtained from the parents at each control. Complete peripheral blood counts, urinary analysis, blood creatinine, and alanine and aspartate aminotransferase levels were also monitored, as were EEG and, when possible, blood levels of concomitant AEDs. 
Statistical analysis
Proportions were compared using Fisher's exact test. Quantitative variables were compared using Student's t test or the two-tailed Wilcoxon rank sum test.
Results
The median follow-up period was 11 months (range 3-27 months; mean 14 AE 6.4 months). Mean TPM dose was 5.2 mg/kg per day (range 1.6-8.9 mg/kg per day). In patients with infantile spasms, the mean TPM dose was 14.8 mg/kg per day (range 7.5-21 mg/kg per day).
Efficacy
Twenty-eight patients (47%) were considered responders because they presented with a reduction of more than 50% in their seizure frequency. In the remaining 31 patients, the drug treatment had been tapered off because of inefficacy or the appearance of adverse events. In detail, eight children (13%) became seizure-free, 20 (34%) displayed a seizure reduction of 50-99%, and 16 (28%) had a minimal response. In a further 10 patients (17%), seizure frequency remained unchanged, whereas five (8%) experienced an increase in the frequency of seizures. In seizure-free patients, the median followup period was 7 months (range 4-16 months). With respect to the type of epilepsy, TPM appeared more effective in LRE (48% of responders) than in generalized epilepsy (32% of responders), although the difference was not statistically significant between these two groups (P = 0.881 by Fisher's exact test; data not shown). With idiopathic LRE, the patient with early-onset occipital seizures still had seizures while treated with TPM, whereas the patient affected by benign partial epilepsy of infancy with secondarily generalized seizures was included among the responders. TPM controlled seizures in the latter patient, with the exception of those triggered by fever, which were still occurring at the last visit. Five of seven patients with cryptogenic LRE were responsive to treatment, as were 7 of 12 patients with symptomatic LRE. Overall, in three patients (one with cryptogenic and two with symptomatic LRE) defined as ''responders'', febriletriggered seizures were still observed at the last visit. The highest responder rates among patients with generalized epilepsy were among those with cryptogenic infantile spasms (four of six became seizure-free), and two of these were placed on TPM monotherapy. Of the 13 patients with symptomatic infantile spasms, only one was seizure-free (7%) and another three were considered responders. In the same group, there was a patient with Ohtahara syndrome and another affected by myoclonic epilepsy with recurrent myoclonus status in nonprogressive encephalopathy, who were both unresponsive to treatment. Two responders (33%) were also observed among the six patients with Dravet's syndrome, and three responders (9%) were observed among the patients with an unclassifiable epilepsy syndrome. An increase or worsening of seizure frequency or severity was observed in two patients (9%) with symptomatic LRE and three (13%) with generalized epilepsy (the latter patients were all affected by symptomatic infantile spasms).
Safety
Adverse events occurred in 22 patients (37% of the total initial treatment group). In five patients, more than one side effect occurred. The most frequently reported treatment-related side effects were drowsiness and nervousness, 11 hyperthermia, 11 and weight loss (eight patients). Hyperthermia was observed only during summer months. It was severe (above 38.5 8C) in one patient, in whom rapid normalization of body temperature was observed when TPM treatments were tapered off. In 10 patients, body temperature was mildly increased ranging from 37.5 to, sporadically, 38 8C. In this group, side effects were controlled by reducing the TPM dose. For technical reasons, no patient underwent the pilocarpine iontophoresis sweat test. However, other possible causes of fever have been adequately excluded. In two patients (one with cryptogenic LRE and another with symptomatic LRE) who were responsive to the drug, severe anorexia occurred at a dose of 4 and 6.2 mg/kg per day, respectively. Reducing these doses led to the disappearance of the adverse effects, but an increase in seizure frequency occurred in one of these patients. Slower titration of the drug was therefore instituted, with no appearance of side effects. Hemathological and biochemical tests resulted normal in all patients.
Discussion
Topiramate is currently approved in Italy for the treatment of patients older than 2 years of age with partial seizures and secondary generalized epilepsy, as well as seizures associated with Lennox-Gastaut syndrome. This paediatric open uncontrolled study is one of the few attempts to evaluate the efficacy of TPM in infants aged less than 2 years, in terms of epilepsy syndromes. Although previous reports seemed to suggest that TPM may be effective in infants with epilepsy, very few cases have been reported in the literature. About 55 were treated for infantile spasms, 9,18-22 less than 20 for Dravet's syndrome, 21, 23, 24 and a number of patients were treated for partial seizures. 6, 20, 21, 25 Furthermore, the majority of these studies were performed to evaluate TPM efficacy against specific seizure types. Because the same type of seizure may be differently responsive to an AED, depending on the epilepsy syndrome for which it is prescribed, it is of cardinal importance to evaluate the efficacy of an AED according to epilepsy syndrome. This concept is particularly true in paediatric populations, in which a wide spectrum of epileptic syndromes is observed. 21, 26 Several studies have established TPM efficacy in partial seizures. A double-blind trial in partial-onset seizures showed 39% of patients with seizure reduction of at least 50% and, in a long-term study, 14% of patients were seizure-free, with 75% continuing on TPM therapy. 25 Many open trials involving children with partial epilepsy confirmed the observations of Elterman et al. 2, 5, [27] [28] [29] In their open-label, prospective study, Mikaeloff et al. 21 observed that among patients with LRE, the percentage of responders was higher (75%) among those aged less than 4 years, prompting the authors to remark that young patients tend to respond better to TPM therapy than older ones. In the present study, we obtained similar results, with 64% of responders among young patients with LRE, confirming the effectiveness of TPM in infants presenting with this type of epilepsy. Globally, data available in the literature refer to the efficacy of TPM in refractory or catastrophic partial epilepsy. In contrast, the effects of TPM in more benign forms of LRE in infancy remain to be established. 20 In this context, we found good responsiveness in a patient affected by benign partial epilepsy of infancy with secondarily generalized seizures but not in a patient with early-onset idiopathic occipital epilepsy, who still experienced seizures at the last visit.
Most available information on the effectiveness of TPM in generalized epilepsy syndromes relates to its role in infantile spasms, for which TPM was found to be useful. In a pilot study involving 11 patients subjected to TPM treatment, seven were still seizure-free after 18 months. 8, 9 In a retrospective study, four of seven patients with refractory infantile spasms were also seizure-free. 18 Herranz reported his experience with open-label TPM use in 13 patients with West syndrome. Nine infants received TPM as the first-line drug, at a maximum dose of 16 mg/kg per day. Two patients became seizure-free and seven were defined as responders. 22 Watemberg et al. reported that TPM was able to reduce seizures in seven of eight patients with refractory infantile spasms and, in three of these, TPM monotherapy was undertaken. 20 In contrast, negligible TPM efficacy was achieved by Mikaeloff et al. in a sample of 14 patients with infantile spasms, none of whom became seizurefree. 21 Nineteen patients affected by infantile spasms were included in our series. The therapeutic protocol we adopted in our institute included the use of vigabatrin as the first-line drug. When total control of seizures, which is the required response in this particular type of epilepsy syndrome, 30 was not achieved, rapid titration of TPM up to 20-25 mg/kg per day was attempted, when lower doses produced a significant reduction in seizure frequency. Therapies with ACTH, valproate, and clonazepam are usually instituted subsequently. Four of six patients with cryptogenic infantile spasms were seizure-free after a median follow-up period of 14 months, and two of these were placed on TPM monotherapy. On the other hand, only 1 of 13 patients with secondary infantile spasms became seizure-free. When patients with cryptogenic infantile spasms are considered, the results observed in the present series are consistent with those of Glausers 8, 9 and Thijs.
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In contrast, the poor results obtained for symptomatic infantile spasms are in line with those observed in the study of Mikaeloff et al. 21 TPM was also unable to control seizures in two patients affected by Ohtahara syndrome or myoclonic epilepsy with recurrent myoclonic status in non-progressive encephalopathy.
In other types of epilepsy syndromes, such as Dravet's syndrome (severe myoclonic epilepsy of infancy), TPM was also effective in that significant seizure reduction was reported in 55% of patients, including 15% of patients who became seizurefree. 23, 24 In contrast, we had poorer results; only two patients (33%) were responders and in neither was complete control of seizures achieved.
Six patients displayed both febrile and afebrile seizures in their epileptic profiles. Two patients were unresponsive to TFM treatment. In the four responsive patients, all affected by LRE, TPM was unable to control those seizures triggered by febrile illnesses. Few data are available in the literature on this point. Our observations seem to indicate negligible efficacy of TPM in controlling febrile-triggered seizures, at least in the present series of patients.
With respect to tolerability, it is well known that the side effects of TPM treatment are mainly represented by behavioural and cognitive difficulties, with an incidence of almost 50% in one retrospective review of 174 adult patients. 31 In contrast, doubleblind studies in children recorded weight loss and sedation as the most common complaints. 6, 25 In open studies, adverse events were observed in 25% of children. 24 Weight loss was reported to occur at variable frequencies, ranging from 6% 32 to around 40%. 33, 34 Reversible language regression was also recently reported. 35 Mikaeloff et al. found that TPM was generally better tolerated in younger than in older children. 21 In the present study, adverse events occurred at a rate of 37% and mainly presented as drowsiness, irritability, anorexia, weight loss, and hypohydrosis. This led to discontinuation of the drug in three patients. In general, adverse events were mild in severity and were often resolved by slowing the rate of TPM titration or reducing the daily dose of the drug. Of course, it was very difficult to evaluate side effects such as sedation and slow thinking, reported to occur in patients treated with TPM, because of the age of the patients, most of who had psychomotor retardation. Gastrointestinal effects, reported in previous studies, 36 were not observed in the present series. Moreover, no ophthalmological side effects were observed, such as acute angle-closure glaucoma, myopia, retinal striae, and uveitis, 31, 37 although no systematic instrumental investigations were performed. In 58% of patients, TPM was administered in association with valproate. Several hematochemical investigations detected no side effects resulting from such a combination, as have been described elsewhere. 19, 38 With respect to hypohydrosis and related hyperthermia, recent reports have shown that up to 65% of patients subjected to TPM therapy had a reduced quantity of sweat in the pilocarpine iontophoresis sweat test. However, only a minority of them was aware of heat intolerance. [39] [40] [41] We believe that is very difficult to establish exactly the frequency of such an adverse event because it is directly related to the environmental temperature. Of course, owing to the age of our patients, it was very difficult to evaluate possible heat intolerance. However, hyperthermia was observed in 11 patients (18%). It was exclusively observed during summer months (especially in summer 2003, when temperatures were very high in Italy). In only one patient was hyperthermia so severe that it prompted us to taper off therapy. In the remaining group of patients, body temperature was mildly increased ranging from 37.5 8C to, sporadically, 38 8C. It reversed to normal values after the dose of TPM was reduced.
In conclusion, the present open, prospective, and pragmatic study confirms that TPM is effective across a broad range of seizure types in children aged less than 2 years. Moreover, our data clearly indicate the usefulness of TPM in cryptogenic infantile spasms. In contrast, poor efficacy was observed in symptomatic infantile spasms and in Dravet's syndrome. Good responsiveness was observed in refractory LRE. TPM appears to be a relatively well-tolerated drug and a slow progressive titration helps to reduce adverse effects. Therefore, TPM should be considered a valid therapeutic option in infants and young children affected by epilepsy.
